PKI-166 is a potent and selective oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM). It has demonstrated efficacy in inhibiting the growth and metastasis of various human cancer cell lines, including pancreatic cancer, in both in vitro and in vivo preclinical studies.
Molekulargewicht:
330.38
Reinheit:
99.80% (May vary between batches)
CAS Nummer:
[187724-61-4]
Formel:
C20H18N4O
Target-Kategorie:
EGFR,VEGFR
Anwendungsbeschreibung:
Solubility: DMSO:27.5 mg/mL (83.24 mM)
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten